Gillian brings Avalere’s FDA practice her immense background in both the public and private sectors, as well as a deep understanding of the biotech and biologics industries.
Given the current landscape at FDA, now is a great time to reach out to Gillian. Over the past few weeks, the Agency has unveiled its first biosimilar filing, followed by its first biosimilar application for a Monoclonal Antibody.
Want to find out what’s to come at FDA and learn about the surging biosimilar industry? Contact Gillian at GWoollett@Avalere.com.